anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Examples are disclosed that relate to performing computer-based well being assessments and proactively performing computer-based mitigation operations to improve a user's well being. In one example, a computing system comprises a network communication subsystem, an attribution machine, a well being assessment machine, and a mitigation machine. The network communication subsystem is configured to communicate with a plurality of user computers. The attribution machine is configured to attribute, to a user account, computing information that the network communication subsystem receives from a user computer. The well being assessment machine is configured to progressively update a well being score over time for the user account based at least on the computing information. The mitigation machine is configured to perform a mitigation operation associated with the user account based at least on an above threshold rate of decrease of the well being score.
Marginal bone changes after 1 year after implant installation using Neo dental implant Alpha Bio Tec. Ltd.
The invention discloses a Chinese herbal medicine application for treating fracture and a preparation method thereof. The Chinese herbal medicine application comprises the components in percentage by weight as follows: 18-20% of flowers carthami, 18-20% of lap waste, 8-10% of dotted ardisia, 10-12% of Glechomalongituba, 8-10% of Commelina diffusa and 8-10% of Chinese Elder Herb. The Chinese herbal medicine application disclosed by the invention for treating fracture is short in treatment period, quick in fracture-setting effect, low in cost and free from toxic and side effects. According to the Chinese herbal medicine application disclosed by the invention, a steel plate or a steel nail is not required to fix, and gypsum is further not used to fix, thus, alleviating pain and inconvenience of patients. The Chinese herbal medicine application disclosed by the invention can be randomly detached to see the affected parts, so that the preparation is convenient and simple. In addition, the treatment cost is further relatively low and within 50-500 yuan for treating the fracture.
The 3 planned dose levels of KAND567 were based on preliminary data from previous i.v. infusions and were chosen to obtain approximate Css levels of 0.5, 1.0 and 2.0 μM. The dose levels were 33.8 mg/6 h (cohort 1), 67 mg/6 h (cohort 2), or 134 mg/6 h (cohort 3).

Each cohort of participants was planned to consist of 8 subjects (2 on placebo and 6 on active drug), i.e. a total of 24 subjects. A sentinel approach was used for all three cohorts, starting dosing with two subjects (one on active drug, one on placebo). If safe and tolerable, an additional two or three subjects will be administered. If safe and tolerable, the remaining three or four subjects of the cohort were dosed. There was an evaluation of safety and tolerability from the previous cohort prior to proceeding to the next cohort.
INTRODUCTION: Upper-tight tourniquet is widely used in Total Knee Arthroplasty in different modalities. However, it has been associated with a negative impact on post-operative muscle strength end pain. This study aimed to investigate the effect of tourniquet on post-operative pain and recovery in enhanced recovery joint surgery.
MATERIALS AND METHODS: In this prospective randomized study, we included 116 patients undergoing to TKA. Surgery was performed with a staged use of tourniquet in Group A (58 patients) and without tourniquet in Group B. In the former group a low-pressure tourniquet was deflated after bone cuts to allow hemostasis of posterior recess and re-inflated for cementation. For all patients a multimodal fast-track recovery protocol was used. Time to reach rehabilitation milestones was recorded as primary endpoint. Range of motion, pain, hemarthrosis, total blood loss, surgical field visualization, Knee Score (KS) and Oxford Knee Score (OKS) were considered as secondary outcomes.
RESULTS: . No statistically significant differences were found (group B: average 1.3 ± 0.6 day; group A: average 1.2 ± 0.5 day). Group A had a shorter mean surgical time and a clearer surgical field visualization. Group B had a larger estimated blood loss and hemoglobin drop without a statistically significant difference in the transfusion rate. No differences between the groups were seen in the KS, OKS and range of motion (ROM) and post-operative joint swelling. Pain score was similar between cohorts and recorded thigh pain was surprisingly greater in group B.
DISCUSSION: The use of tourniquet in TKA surgery helps to minimize intraoperative blood loss and improves surgical field visualization. Its application with a modern and staged protocol does not affect the functional outcomes (OKS, KSS, ROM) of the early post operative period without compromising the fast-track recovery.
The natural history of cervical cancer is closely linked to that of high-risk human papillomaviruses (HPV) infection. It is recognized that upon HPV DNA integration, partial or complete loss of the E2 open reading frame precludes expression of the corresponding protein, resulting in upregulation of the E6 and E7 viral oncoproteins. To better characterize HPV16 infection at the cervical level, viral load, viral DNA integration, and viral early transcript expression (E2, E5, and E6) were analyzed in a series of 158 cervical specimens representative of the full spectrum of cervical disease. Overall, the frequency of early transcript detection varied from 45% to 90% and tended to increase with lesion severity. In addition, the levels of E2, E5, and E6 transcript expression were slightly higher in high-grade lesions than in cervical specimens without abnormalities. Notably, early transcript expression was clearly associated with viral load, and no inverse correlation was found between the expression of E2 and E6 transcripts. No clear association was found between early transcript expression and HPV16 DNA integration, with the exception that samples with a fully integrated HPV16 genome did not harbor E2 or E5 transcripts. In conclusion, early HPV16 transcript expression appears to be associated with viral load rather than lesion grade. From a practical point of view, quantification of HPV16 early transcripts is difficult to translate into a relevant biomarker for cervical cancer screening.
INTRODUCTION: Early sepsis treatment in the emergency department (ED) is crucial to improve patient survival. Despite international promulgation, the uptake of the Surviving Sepsis Campaign (SSC) Hour-1 Bundle (lactate measurement, blood culture, broad-spectrum antibiotics, 30 mL/kg crystalloid for hypotension/lactate ≥4 mmol/L and vasopressors for hypotension during/after fluid resuscitation within 1 hour of sepsis recognition) is low across healthcare settings. Delays in sepsis recognition and a lack of high-quality evidence hinder its implementation. We propose a novel sepsis care model (National Early Warning Score, NEWS-1 care), in which the SSC Hour-1 Bundle is triggered objectively by a high NEWS-2 (≥5). This study aims to determine the feasibility of a full-scale type 1 hybrid effectiveness-implementation trial on the NEWS-1 care in multiple EDs.
METHODS AND ANALYSIS: We will conduct a pilot type 1 hybrid trial and prospectively recruit 200 patients from 4 public EDs in Hong Kong cluster randomised in a stepped wedge design over 10 months. All study sites will start with an initial period of standard care and switch in random order at 2-month intervals to the NEWS-1 care unidirectionally. The implementation evaluation will employ mixed methods guided by the Reach, Effectiveness, Adoption, Implementation and Maintenance framework, which includes qualitative and quantitative data from focus group interviews, staff survey and clinical record reviews. We will analyse the 14 feasibility outcomes as progression criteria to a full-scale trial, including trial acceptability to patients and staff, patient and staff recruitment rates, accuracy of sepsis screening, protocol adherence, accessibility to follow-up data, safety and preliminary clinical impacts of the NEWS1 care, using descriptive statistics.
ETHICS AND DISSEMINATION: The institutional review boards of all study sites approved this study. This study will establish the feasibility of a full-scale hybrid trial. We will disseminate the findings through peer-reviewed publications, conference presentations and educational activities.
TRIAL REGISTRATION NUMBER: NCT05731349.
PURPOSE:A cataplasma obtained by incorporating a cataplasma base containing water with a surfactant having a specific HLB value and an active constituent insoluble or sparingly soluble in water. CONSTITUTION:A cataplasma, obtained by incorporating a hydrous cataplasma base, e.g. hydrous gel base crosslinkable with metallic ions (preferably nongelatin type base containing polyacrylic acid and polyacrylate and further sodium carboxymethyl cellulose and/or alkali metal alginate0 with 0.1-40wt% surfactant having 1-9 HLB value, e.g. sorbitan ester of a fatty acid, and 0.01-20wt% active constituent insoluble or sparingly soluble in water, e.g. indomethacin, and having high percutaneous absorption of the active constituent. The above-mentioned composition permits the stable compounding of the active constituent insoluble or sparingly soluble in water and high percutaneous absorption of the active constituent. KABURE, etc. is not easily caused in the skin, and the safety is excellent.
After tracheal intubation, a high-frequency linear probe will be placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will be inserted with in-plane technique and 25 ml 0.25 bupivacaine will be applied to the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side. The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.
Neutrophils are the first line of defense against invading pathogens. Neutrophils execute and modulate immune responses by generating reactive oxygen species (ROS). Chronic granulomatous disease (CGD) is a primary immune deficiency disorder of phagocytes, caused by inherited mutations in the genes of the nicotinamide adenine dinucleotide phosphate reduced oxidase enzyme. These mutations lead to failure of ROS generation followed by recurrent bacterial and fungal infections, frequently associated with hyperinflammatory manifestations. We report a multicenter cumulative experience in diagnosing and treating patients with CGD. From 1986 to 2021, 2918 patients experiencing frequent infections were referred for neutrophil evaluation. Among them, 110 patients were diagnosed with CGD: 56 of Jewish ancestry, 48 of Arabic ancestry, and 6 of non-Jewish/non-Arabic ancestry. As opposed to other Western countries, the autosomal recessive (AR) CGD subtypes were predominant in Israel (71/110 patients). Thirty-nine patients had X-linked CGD, in most patients associated with severe infections (clinical severity score ≥3) and poor outcomes, presenting at a significantly earlier age than AR-CGD subtypes. The full spectrum of infections and hyperinflammatory manifestations is described. Six patients had hypomorphic mutations with significantly milder phenotype, clinical severity score ≤2, and better outcomes. Hematopoietic stem cell transplantation was implemented in 39 of 110 patients (35.5%). Successful engraftment was achieved in 92%, with 82% long-term survival and 71% full clinical recovery. CGD is a complex disorder requiring a multiprofessional team. Early identification of the genetic mutation is essential for prompt diagnosis, suitable management, and prevention.
This trial will evaluate, in patients with metastatic prostate cancer, the tolerability, toxicities, efficacy, and immunologic effects of repeated vaccinations with a recombinant vaccinia virus that contains the Prostate Specific Antigen gene (PROSTVAC). Patients with PSA-expressing adenocarcinoma of the prostate will be evaluated for eligibility that includes a history of prior vaccinia (as vaccine against smallpox) and immunocompetence. We completed a phase I trial investigating the use of rV-CEA in adenocarcinomas of the GI tract, lung and breast. The toxicities encountered are local reactions to the vaccine. We did not encounter any myelosuppression or systemic autoimmune reaction. We would like to evaluate four doses to ensure safety and to decide a best biological dose. Six patients will receive 2.65 x 10(5) PFU and 2.65 x 10(6) PFU of vaccine by scarification. Because higher doses cannot be achieved by scarification, six patients will receive 2.65 x 10(7) PFU and 2.65 x 10(8) PFU subcutaneously. We plan to give three vaccinations at four week intervals. All six patients treated in each dose level must be evaluable for 4 weeks before enrolling patients at the higher dose level. No intrapatient escalation is planned. Toxicity, tumor response, and humoral and cellular immunity factors will be monitored. Optional lymphapheresis will be done on patients that are HLA A2. Once we determined the best biological dose, we would like to accrue an additional 6 patients to that level.
Aristolochiaic esters of formula (I) comprises irradiating a soln. of the iodo-cis-stilbene of formula (II) in a lower alkanol with light, pref. of wavelength 253.7nm, from a low pressure Hg lamp. (R = lower alkyl; R1 and R2 = H or CH3O). (I) neutralise the effects of insect and snake poisons, are useful in treatment of puerperal fever; inhibit adenocarcinoma 755 and stimulate phagocytosis of leucocytes. High yields are achieved using much less solvent than when cyclohexane is used in place of alcohol. (I) is recovered in crystalline form and does not tend to undergo further reactions.
510,118. Medicines ; calcium salts. WULFING, G. A. R. VON, and ROSSKOTHEN, E. M. H., (trading as WULFING, J. A.). Aug. 8, 1938, No. 23386. Convention date, Aug. 6, 1937. [Class 81(i)] [Also in Group IV] Stable solutions of organic calcium salts suitable for parenteral injection are prepared by adding malic acid or a sodium salt thereof to the solutions of the calcium salts. The malic acid or malate may be added to hot solutions of the calcium salts, and the malate may be prepared in situ. Examples are given of the treatment of calcium lactate and calcium sodium lactate solutions. The Specification as open to inspection under Sect. 91 refers also to the use of other organic hydroxyacids and their salts instead of malic acid, mandelic acid and salts thereof being specified. An example of the treatment of calcium gluconate solution with sodium malate is also included. This subject-matter does not appear in the Specification as accepted.
Adults and children with sickle cell disease (SCD) are predominantly African American, with pain-related health disparities. We examined opioid prescription fill patterns in adults and children with SCD and compared factors associated with fills in North Carolina Medicaid enrollees. Our retrospective cohort study included 955 enrollees diagnosed with SCD having at least one opioid fill. Associations were measured between two cohorts (12 and 24 mo of continuous enrollment) for the following characteristics: sex, age, enrollee residence, hydroxyurea adherence, comanagement, enrollment in Community Care North Carolina, prescription for short versus short and long-acting opioids, and emergency department reliance. The majority of individuals did not have an opioid claim over a 12 or 24-month period. Claims increased at ages 10 to 17, peaking at ages 18 to 30. The increased number of claims was associated with the following factors: increasing age, male, short versus long-acting opioids, and Medicaid enrollment for 24 versus 12 months. Community Care North Carolina enrollees in the 12-month cohort had higher opioid days of supply per month; the inverse was true of the 24-month cohort.
Epilepsy is a neurological disease characterized by repeated seizures. Despite of that the brain-derived neurotrophic factor (BDNF) is implicated in the pathogenesis of epileptogenesis and epilepsy, BDNF may have a neuroprotective effect against epilepsy. Thus, the goal of the present review was to highlight the protective and detrimental roles of BDNF in epilepsy. In this review, we also try to find the relation of BDNF with other signaling pathways and cellular processes including autophagy, mTOR pathway, progranulin (PGN), and α-Synuclein (α-Syn) which negatively and positively regulate BDNF/tyrosine kinase receptor B (TrkB) signaling pathway. Therefore, the assessment of BDNF levels in epilepsy should be related to other neuronal signaling pathways and types of epilepsy in both preclinical and clinical studies. In conclusion, there is a strong controversy concerning the potential role of BDNF in epilepsy. Therefore, preclinical, molecular, and clinical studies are warranted in this regard.
The invention belongs to the field of traditional Chinese medicine, and in particular relates to a traditional Chinese medicine composition for treatment of damp-heat jaundice. The title of invention is a traditional Chinese medicine for treatment of damp-heat jaundice and preparation method, test method as well as application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-3 parts of Herba Barleriae Lupulinae, 1-3 parts of Creeping Dichondra Herb, 1-3 parts of Diospyros rhombifolia, 1-3 parts of Tirpitzia ovoidea, 1-3 parts of Gupiteng and 1-3 parts of Semen Abietis Delavayi. The preparation method comprises the following steps of: mixing dry Herba Barleriae Lupulinae, Creeping Dichondra Herb, Diospyros rhombifolia, Gupiteng and Semen Abietis Delavayi together, adding water in an amount of 5-15 times of that of medicinal materials into the medicinal materials, performing microwave extraction for 1-5 times, and lasting 15-60 minutes each time, combining extract solution, concentrating, drying, and crushing into fine powder, adding adjuvants, mixing evenly, forming granules, thereby obtaining the medicine composition. The invention also provides a quality test method of the traditional Chinese medicine composition. The traditional Chinese medicine composition also can be used for preparing traditional Chinese medicines for treatment of liver cirrhosis.
The participants will undergo the water drinking test as previously described, i.e. after drinking 800 mls of water over a 5 minute period, the intraocular pressure will be measured immediately after completion of ingestion, followed by intraocular pressure measurements every 15 minutes for 60 minutes, using etc Goldmann apllantion tonometer.
BACKGROUND: Hypertensive crises in children represent critical medical situations characterized by severe hypertension and potential organ damage. Fenoldopam, a dopaminergic medication, offers a viable therapeutic option for managing such clinical scenarios. We aimed to evaluate efficacy and safety of fenoldopam in the management of hypertensive urgencies and emergencies.
METHODS: This retrospective analysis focused on pediatric patients affected by acute or chronic kidney disease, aged 1 month-18 years, admitted to the Pediatric Nephrology and the Pediatric Intensive Care Unit at University-Hospital of Padua, Italy, who presented with a hypertensive crisis treated with fenoldopam between March 2010 and December 2022.
RESULTS: The study included 74 patients with median age 10 years (interquartile range [IQR] 4-15 years) who received 102 fenoldopam infusions. Seventy-two percent were already receiving antihypertensive treatment before admission. In all cases, fenoldopam was associated with a reduction of blood pressure (BP) after 8 h of treatment, but in 87% of patients reduction of the initial mean arterial pressure (MAP) was higher than 25% of calculated drop pressure. MAP normalized in 26% of cases after 24 h and in 35% after 48 h. Occurrence of hypotension was 7%, while hypokalemia was observed in 13% of cases. Patients who presented a MAP reduction not exceeding 25% of calculated drop pressure received a lower median fenoldopam dose (0.2 mcg/kg/min; IQR 0.1-0.2) compared with patients having a MAP reduction > 25% of calculated drop pressure (0.4 mcg/kg/min; IQR 0.2-0.6; p = 0.002).
CONCLUSIONS: Fenoldopam seems effective and safe for the treatment of hypertensive crises in children with kidney disease, at a starting dose of 0.2 mcg/kg/min. Strict BP monitoring is required to identify possible excessive drop pressure in the first hours of infusion.
has diabetes. Postmenopausal Osteoporosis (PMO) is an increasingly serious metabolic bone disease in the world, which generally develops in middle-aged and elderly women and postmenopausal women, and it is characterized by low bone mass and microstructure degradation of bone tissues. there are complex pathophysiological effects between them: T2D directly affects bone metabolism and strength. Some antidiabetic drugs affect bone metabolism, and diabetes complications are related to the risk of falls and subsequent fractures. Patients with T2D have higher trabecular and lower cortical bone density, leading to lower bone intensity. Exercise is considered a highly relevant component in the prevention and treatment of osteoporosis and fracture reduction. Exercise greatly affects bone geometry as it increases periosteal apposition through increasing osteoblast formation. In addition to influencing bone mineral density, exercise can improve muscle function to potentially decrease fall risk through improved balance and strength.

The purpose of this study was to investigate the effect of moderate-intensity aerobic exercise versus resistance exercise on bone mineral density in postmenopausal diabetic women.
Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy in previous interventional Phase 3 trial FIGARO-DKD. No new intervention was administered in this biomarker study.
A composition which contains a Laurus nobilis leaf extract for preventing and treating hepatic cirrhosis and hepatic fibrosis is provided to prevent hepatocyte apoptosis and oxidative hepatocyte damage and induce the apoptosis of hepatic stellate cell. A composition for treating or preventing hepatic fibrosis and hepatic cirrhosis comprises active amount of Laurus nobilis leaf extract. The Laurus nobilis leaf extract is alcohol extract and chloroform fraction of the laurel tree leaf extract. The daily dose of the laurel tree leaf extract is 1-2,000mg/kg body weight. The composition is used in a form of pill, drink medicine, and medicinal drug. The composition further comprises excipient, carrier or diluents.